Geron Corp. buy melinda
Start price
03.09.12
/
50%
€2.25
Target price
04.03.13
€2.80
Performance (%)
-51.11%
End price
04.03.13
€1.10
Summary
This prediction ended on 04.03.13 with a price of €1.10. Massive losses of -51.11% were the result for the BUY prediction by melinda. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Geron Corp. | 0.638% | 0.638% | 18.156% | -53.585% |
| iShares Core DAX® | 0.855% | 0.389% | 2.533% | 52.003% |
| iShares Nasdaq 100 | -0.989% | -4.400% | 25.154% | 77.536% |
| iShares Nikkei 225® | -1.781% | -11.216% | 44.398% | 64.676% |
| iShares S&P 500 | 0.057% | 0.778% | 20.953% | 63.009% |
Comments by melinda for this prediction
In the thread Geron Corp. diskutieren
pharma
Geron Corp ist ein biopharmazeutisches Unternehmen, das therapeutische Klasse für Krebs entwickelt (Brust, Lunge)
(Laufzeit überschritten)